Terumo (TSE:4543) Debt-to-Asset : 0.13 (As of Mar. 2024)

View and export this data going back to 1982. Start your Free Trial

What is Terumo Debt-to-Asset?

Terumo's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円156,870 Mil. Terumo's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was 円74,978 Mil. Terumo's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was 円1,831,402 Mil. Terumo's debt to asset for the quarter that ended in Mar. 2024 was 0.13.

Terumo Debt-to-Asset Historical Data

The historical data trend for Terumo's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terumo Debt-to-Asset Chart

Terumo Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

Get a 7-Day Free Trial

0.20

0.19

0.15

0.13

Terumo Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.15	0.14	0.13	0.13	0.13

Competitive Comparison of Terumo's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Terumo's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Terumo's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Terumo's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Terumo's Debt-to-Asset falls into.

Terumo Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Terumo's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(156870	+	74978)	/	1831402
	=	0.13

Terumo's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(156870	+	74978)	/	1831402
	=	0.13

Terumo (TSE:4543) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Terumo Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Terumo's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Terumo (TSE:4543) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Terumo Corp (TSE:4543) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

TRUMY:USA TRUMF:USA TUO:Germany

Address

2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072

Website

https://www.terumo.com

Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.

Terumo (TSE:4543) Headlines

No Headlines